Compare ULH & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ULH | DBVT |
|---|---|---|
| Founded | 1932 | 2002 |
| Country | United States | France |
| Employees | N/A | 90 |
| Industry | Trucking Freight/Courier Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 780.8M | 635.3M |
| IPO Year | 2004 | 2014 |
| Metric | ULH | DBVT |
|---|---|---|
| Price | $29.34 | $11.45 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $37.16 |
| AVG Volume (30 Days) | 70.4K | ★ 336.9K |
| Earning Date | 10-29-2026 | 10-28-2026 |
| Dividend Yield | ★ 1.43% | N/A |
| EPS Growth | N/A | ★ 10.26 |
| EPS | ★ 0.86 | N/A |
| Revenue | ★ $1,461,708,000.00 | $5,636,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.83 | $1,817.58 |
| P/E Ratio | $34.07 | ★ N/A |
| Revenue Growth | N/A | ★ 35.77 |
| 52 Week Low | $11.73 | $8.63 |
| 52 Week High | $33.87 | $26.19 |
| Indicator | ULH | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 68.48 | 60.98 |
| Support Level | $14.25 | $8.78 |
| Resistance Level | N/A | $12.73 |
| Average True Range (ATR) | 2.47 | 0.73 |
| MACD | 1.06 | 0.27 |
| Stochastic Oscillator | 75.11 | 95.99 |
Universal Logistics Holdings Inc is an asset-light provider of customized transportation and logistics solutions throughout the United States, and in Mexico, Canada, and Colombia. It offers services such as truckload, brokerage, intermodal, dedicated, and value-added services. The firm has three reportable segments, namely contract logistics, intermodal, and trucking. The company generates the key revenue from Contract Logistics, which provides value-added and dedicated transportation services to support inbound and internal logistics requirements of industrial manufacturers and retailers, generally under contractual arrangements of one year or longer. Geographically, the firm generates the majority of its revenue from the United States, followed by Mexico, Canada, and Colombia.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.